- Home
- JWEL vs BGLC Comparison
JWEL vs BGLC Comparison
Compare JWEL & BGLC Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- JWEL
- BGLC
- Stock Information
- Founded
- JWEL 2012
- BGLC 2017
- Country
- JWEL China
- BGLC Malaysia
- Employees
- JWEL N/A
- BGLC N/A
- Industry
- JWEL Other Consumer Services
- BGLC Medical Specialities
- Sector
- JWEL Consumer Discretionary
- BGLC Health Care
- Exchange
- JWEL Nasdaq
- BGLC Nasdaq
- Market Cap
- JWEL 6.0M
- BGLC 5.8M
- IPO Year
- JWEL 2021
- BGLC N/A
- Fundamental
- Price
- JWEL $2.91
- BGLC $0.40
- Analyst Decision
- JWEL
- BGLC
- Analyst Count
- JWEL 0
- BGLC 0
- Target Price
- JWEL N/A
- BGLC N/A
- AVG Volume (30 Days)
- JWEL 17.0K
- BGLC 598.7K
- Earning Date
- JWEL 12-19-2024
- BGLC 02-20-2025
- Dividend Yield
- JWEL 7.34%
- BGLC N/A
- EPS Growth
- JWEL N/A
- BGLC N/A
- EPS
- JWEL N/A
- BGLC N/A
- Revenue
- JWEL $160,009,293.00
- BGLC $9,259,858.00
- Revenue This Year
- JWEL N/A
- BGLC N/A
- Revenue Next Year
- JWEL N/A
- BGLC N/A
- P/E Ratio
- JWEL N/A
- BGLC N/A
- Revenue Growth
- JWEL N/A
- BGLC N/A
- 52 Week Low
- JWEL $1.00
- BGLC $0.21
- 52 Week High
- JWEL $3.71
- BGLC $3.39
- Technical
- Relative Strength Index (RSI)
- JWEL 48.97
- BGLC 56.86
- Support Level
- JWEL $2.73
- BGLC $0.37
- Resistance Level
- JWEL $3.08
- BGLC $0.44
- Average True Range (ATR)
- JWEL 0.22
- BGLC 0.04
- MACD
- JWEL -0.03
- BGLC 0.00
- Stochastic Oscillator
- JWEL 41.38
- BGLC 54.46
About JWEL Jowell Global Ltd.
Jowell Global Ltd is a cosmetics, health and nutritional supplements, and household products e-commerce platform. It operates under Online Direct Sales, Authorized Retail Store Distribution, Third-party Merchants, and Live streaming marketing sales channels. The company's major merchandise categories are Cosmetic products, Health and nutritional supplements, and Household Products.
About BGLC BioNexus Gene Lab Corp Common stock
BioNexus Gene Lab Corp through its wholly owned subsidiary, focuses on the sale of chemical raw materials for the manufacture of industrial, medical, appliance, aero, automotive, mechanical, and electronic industries in the Southeast Asia region. These countries include Malaysia, Indonesia, Vietnam, and other countries in Southeast Asia. In addition, the Company is in the business of developing and providing safe, effective, and non-invasive liquid biopsy tests for the early detection of biomarkers that it believes are linked to diseases to minimize treatment costs and improve patient management. Its non-invasive blood tests provide analysis of changes in RNA to detect the potential risk of 11 different diseases.